8-K: RxSight Exceeds 2025 Revenue Guidance, Appoints New CFO

RxSight, Inc. announced preliminary unaudited Q4 and full-year 2025 financial results, surpassing its revenue guidance, and appointed Mark Wilterding as its new Chief Financial Officer.

Summary

• Preliminary unaudited fourth quarter 2025 revenue is expected to be approximately $32.6 million.
• 28,611 Light Adjustable Lenses (LAL/LAL+) were sold in Q4 2025, representing a 10% increase in procedure volume compared to Q3 2025.
• 25 Light Delivery Devices (LDDs) were sold in Q4 2025, expanding the installed base to 1,134 LDDs as of December 31, 2025.
• Preliminary unaudited full-year 2025 revenue is expected to be approximately $134.5 million, exceeding the November guidance of $125 million to $130 million.
• 109,615 LALs were sold in full-year 2025, representing a 12% increase in procedure volume compared to 2024.
• 163 LDDs were sold in full-year 2025.
• Cash, cash equivalents, and short-term investments are expected to be $228.1 million as of December 31, 2025.
• Mark Wilterding has been appointed Chief Financial Officer (and principal financial and accounting officer), effective January 11, 2026, replacing Shelley Thunen.

Sentiment

Score: 8

Explanation: The filing reports preliminary financial results that exceeded revenue guidance, indicating strong operational performance. The appointment of a highly experienced CFO from leading Medtech companies further strengthens management and signals a focus on future growth and financial rigor. The unique product offering and growing market penetration are significant positives.

Positives

• Full-year 2025 revenue of approximately $134.5 million exceeded the company's November guidance of $125 million to $130 million.
• Q4 2025 Light Adjustable Lens (LAL/LAL+) procedure volume increased by 10% compared to Q3 2025, with 28,611 lenses sold.
• Full-year 2025 LAL sales increased by 12% compared to 2024, with 109,615 lenses sold.
• The installed base of Light Delivery Devices (LDDs) expanded to 1,134 as of December 31, 2025, with 25 LDDs sold in Q4 and 163 in full-year 2025.
• The company holds approximately 10% share of the premium IOL market and has adoption by over 25% of U.S. cataract surgeons.
• Strong cash position with $228.1 million in cash, cash equivalents, and short-term investments as of December 31, 2025.
• Appointment of an experienced Chief Financial Officer, Mark Wilterding, with a strong background in Medtech finance and investor relations from Edwards Lifesciences and Medtronic.

Risks

• Preliminary unaudited financial and operational results are subject to the completion of the company's 2025 audit, and actual reported results could differ.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied.
• Risks are described in the company's prior press releases and SEC filings, including Part II, Item 1A (Risk Factors) of the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 5, 2025, and any subsequent filings.

Future Outlook

The company anticipates continued stabilization and recovery in procedure trends, deepening customer relationships through its unified commercial team, and sustained, long-term growth driven by its expanding LDD installed base, increasing premium IOL market share, and adoption by a growing percentage of U.S. cataract surgeons. The company aims to continue innovating its adjustable IOL technology and products to redefine the premium category and drive long-term shareholder value.

Management Comments

• "Procedure trends during the quarter reflected a continued, measured pace of stabilization and recovery, and we remain encouraged by strong engagement across the field as our unified commercial team deepens customer relationships." Ron Kurtz, Chief Executive Officer and President.
• "Despite headwinds in 2025, our team made meaningful progress, enabling us to treat more patients than ever before." Ron Kurtz, Chief Executive Officer and President.
• "With more than 1,100 LDDs installed, approximately 10% share of the premium IOL market, and adoption by over 25% of U.S. cataract surgeons, we exited the year in a strengthened position for sustained, long-term growth." Ron Kurtz, Chief Executive Officer and President.
• "Mark has a proven track record of building strong teams, partnering with key Medtech stakeholders, and driving operational excellence. His leadership and expertise will be particularly valuable as we continue to position RxSight for the future." Ron Kurtz, Chief Executive Officer and President, on Mark Wilterding.
• "I am thrilled to be joining RxSight, a company offering the only adjustable IOL technology, which is redefining the premium category. RxSight products deliver meaningful value to patients and surgeons, and I am looking forward to supporting their continued advancement as we aim to drive long-term, sustainable growth and shareholder value." Mark Wilterding, new Chief Financial Officer.

Industry Context

RxSight operates in the ophthalmic medical device sector, specifically targeting cataract surgery patients with its unique Light Adjustable Lens (LAL) technology. The company's reported growth in LAL procedure volume and LDD installations, coupled with its stated 10% share of the premium IOL market and adoption by over 25% of U.S. cataract surgeons, indicates a strong competitive position and increasing penetration in a specialized segment. The appointment of a CFO with extensive experience from major Medtech players like Edwards Lifesciences and Medtronic suggests a strategic focus on scaling financial operations and investor relations to support continued expansion in this innovative market.

Comparison to Industry Standards

• The company's Light Adjustable Lens (LAL) system is highlighted as the "first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery," positioning it uniquely in the premium IOL market.
• Achieving approximately 10% share of the premium IOL market suggests significant traction against established competitors in the broader IOL segment, such as Alcon (with its AcrySof IQ PanOptix and Vivity IOLs) and Johnson & Johnson Vision (with its TECNIS Symfony and Eyhance IOLs), which offer multifocal and extended depth of focus lenses but lack post-operative adjustability.
• Adoption by over 25% of U.S. cataract surgeons indicates a strong and growing acceptance rate for a specialized technology, potentially outpacing the initial adoption curves of other novel IOL technologies that require new surgical protocols or equipment.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to exceeding revenue guidance, strong operational metrics (LAL sales, LDD installed base), and the appointment of an experienced CFO, potentially leading to increased investor confidence and share price appreciation.
• Employees: The appointment of a new CFO may bring new leadership and strategic direction to the finance organization.
• Customers (Cataract Surgeons): Continued expansion of the LDD installed base and increasing LAL adoption indicates growing satisfaction and utilization of the company's unique adjustable IOL technology.
• Patients: More patients are being treated with the Light Adjustable Lens system, offering customized vision post-cataract surgery.

Next Steps

• Completion of the company's 2025 audit.
• Announcement of audited full-year 2025 financial results and full-year 2026 guidance in February 2026.
• Filing of the full text of the Employment Agreement and Severance Agreement as exhibits to a subsequent periodic report.
• Continued advancement of RxSight products to drive long-term, sustainable growth and shareholder value.

Key Dates

Recommendation

The company has demonstrated strong operational performance by exceeding its full-year 2025 revenue guidance, indicating robust demand for its unique Light Adjustable Lens technology. The significant increase in LAL procedure volume and expansion of the LDD installed base suggest growing market penetration and adoption by U.S. cataract surgeons. The appointment of Mark Wilterding, a seasoned financial executive from leading Medtech companies, strengthens the management team and signals a strategic focus on scaling operations and enhancing shareholder value. With a healthy cash position and a differentiated product in a growing market, RxSight is well-positioned for sustained long-term growth, making it an attractive investment.

Keywords

RxSight, RXST, Ophthalmic Medical Device, Cataract Surgery, Light Adjustable Lens, LAL, LAL+, Light Delivery Device, LDD, Intraocular Lens, IOL, Financial Results, CFO Appointment, Medtech, Medical Technology, Preliminary Results, Revenue Guidance